4D Molecular Therapeutics (FDMT) Interest & Investment Income (2020 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Interest & Investment Income of $4.9 million for Q1 2026, down 12.86% year-over-year from $5.6 million in Q1 2025, and up 3.4% quarter-over-quarter from $4.7 million in Q4 2025.
4D Molecular Therapeutics (FDMT) Interest & Investment Income (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Interest & Investment Income for 7 consecutive years, with $4.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest & Investment Income fell 12.86% year-over-year to $4.9 million; the TTM figure through Mar 2026 stood at $13.9 million (down 27.42% YoY), while the FY2025 annual figure was $19.5 million, down 28.0% from the prior year.
- Interest & Investment Income climbed to $4.9 million in Q1 2026 per FDMT's latest filing, from $4.7 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $7.3 million in Q3 2024 and bottomed at -$998000.0 in Q1 2022.
- Historically, Interest & Investment Income has averaged $2.6 million across 5 years, with a median of $1.3 million in 2022.
- Annual changes were most pronounced in 2022 — Interest & Investment Income plunged 14357.14% — and 2025, when it surged 4565.6%.
- 4D Molecular Therapeutics' Interest & Investment Income stood at $1.3 million in 2022, then surged by 227.35% to $4.4 million in 2023, then soared by 47.65% to $6.5 million in 2024, then retreated by 27.26% to $4.7 million in 2025, then grew by 3.4% to $4.9 million in 2026.
- Business Quant data shows FDMT's Interest & Investment Income at $4.9 million in Q1 2026, $4.7 million in Q4 2025, and $4.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 48.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 35.58 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 27.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 5.13 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 28.14 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 10.98 Mn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | 4.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.26 Mn |
| Mar 31, 2026 | 4.86 Mn |
| Dec 31, 2025 | 4.70 Mn |
| Sep 30, 2025 | 4.33 Mn |
| Jun 30, 2025 | 5,000.00 |
| Mar 31, 2025 | 5.58 Mn |
| Dec 31, 2024 | 6.47 Mn |
| Sep 30, 2024 | 7.29 Mn |
| Jun 30, 2024 | -184,000.00 |
| Mar 31, 2024 | -125,000.00 |
| Dec 31, 2023 | 4.38 Mn |
| Sep 30, 2023 | 3.88 Mn |
| Jun 30, 2023 | 615,000.00 |
| Mar 31, 2023 | 926,000.00 |
| Dec 31, 2022 | 1.34 Mn |
| Sep 30, 2022 | 795,000.00 |
| Jun 30, 2022 | -406,000.00 |
| Mar 31, 2022 | -998,000.00 |
| Dec 31, 2021 | -312,000.00 |
| Sep 30, 2021 | 435,000.00 |